Albert Bourla

**Albert Bourla** is a Greek-American business executive and veterinarian who has led Pfizer since 2019. He earned a veterinary medicine degree from Aristotle University of Thessaloniki and an MBA from the University of Thessaloniki, joining Pfizer in 1993. He is currently **Pfizer’s chairman and chief executive officer**. Before becoming CEO, he held senior roles overseeing Pfizer’s animal-health, emerging-markets, and pharmaceutical businesses, and served as chief operating officer. Bourla is best known for leading Pfizer during the COVID-19 pandemic, including its partnership with BioNTech to develop and commercialize the **Comirnaty COVID-19 vaccine**, one of the first vaccines authorized for widespread use. He has also overseen Pfizer’s development and rollout of treatments such as **Paxlovid**.

**Albert Bourla** is the **Chairman and CEO of Pfizer**, one of the world’s largest pharmaceutical companies.[1][3] He was **born in Thessaloniki, Greece**, to a family of **Holocaust survivors**, and earned a **Doctor of Veterinary Medicine** plus a **Ph.D. in the Biotechnology of Reproduction** from Aristotle University of Thessaloniki.[1][6] Bourla has spent **more than 30 years at Pfizer**, holding senior roles in multiple countries before becoming CEO in **January 2019**.[1][2] His notable work includes leading Pfizer’s shift toward a more **science-driven strategy**, increasing investment in **R&D and technology**, and overseeing Pfizer during the **COVID-19 vaccine** period.[1][3][12]

# Albert Bourla - Pfizer CEO **Background:** Albert Bourla is a Greek-born veterinarian who joined Pfizer in 1990. He held various leadership positions across the company's divisions before becoming Chief Executive Officer in January 2019. **Current Role:** He serves as CEO and Chairman of Pfizer, one of the world's largest pharmaceutical companies. **Notable Work:** - Led Pfizer's development and distribution of its COVID-19 vaccine (with BioNTech) starting in 2020, which became one of the most widely used vaccines globally - Oversaw significant company acquisitions and restructuring - Became a prominent public figure during the pandemic as a spokesperson for vaccine development and rollout **Other Details:** - Known for his focus on innovation and modernizing Pfizer's operations - Has been a visible advocate for pharmaceutical industry interests This summary reflects information available through early 2024. For the most current information about his role or recent developments, I'd recommend checking recent news sources.

**Albert Bourla** is a Greek-American veterinarian and pharmaceutical executive. * **Current Role:** He is the Chairman and Chief Executive Officer (CEO) of **Pfizer**, having assumed the CEO position in January 2019 and Chairman in February 2020. He has spent his entire career at Pfizer, joining the company in 1993 and holding various leadership roles across its global operations. * **Background:** Born in Thessaloniki, Greece, in 1961, Bourla earned a Doctor of Veterinary Medicine (DVM) and a Ph.D. in biotechnology of reproduction from the Aristotle University of Thessaloniki. * **Notable Work:** Bourla is best known for leading Pfizer through the COVID-19 pandemic. Under his leadership, Pfizer partnered with BioNTech to develop Comirnaty, one of the first and most widely distributed COVID-19 vaccines, in record time (Operation Warp Speed). For this achievement, he was named *Time* magazine's "Businessperson of the Year" for 2021 and received the Genesis Prize in 2022.

**Albert Bourla** is a Greek-American pharmaceutical executive. - **Background**: Born in 1961 in Thessaloniki, Greece; earned a doctorate in veterinary medicine and a PhD in reproduction from Aristotle University of Thessaloniki. He joined Pfizer in 1993 in its animal-health division and advanced through roles in vaccines, oncology, and global operations. - **Current role**: Chairman and CEO of Pfizer Inc. since January 2019 (CEO) and 2020 (Chairman). - **Notable work**: Oversaw Pfizer’s rapid development and global rollout of the Pfizer-BioNTech COVID-19 mRNA vaccine (2020–2021); previously led Pfizer’s animal-health and vaccines businesses and drove the company’s oncology and rare-disease portfolios.